Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study

Overview

Journal Turk J Gastroenterol

Publisher Aves

Specialty Gastroenterology

Date 2022 Jun 9

PMID 35678800

Authors

Vian Ahmed Wasta Esmail

Marwan S M Al-Nimer

Mohammed Omer Mohammed

Affiliations

Soon will be listed here.

Abstract

Background: One of the important inducers of inflammatory responses and accumulation of fat in hepatocytes is free fatty acids which ultimately lead to the development of non-alcoholic fatty liver disease. Patients with non-alcoholic fatty liver disease have high levels of plasma free fatty acids which are usually associated with type 2 diabetes and components of metabolic syndrome including dyslipidemia. Objective of this research is to investigate the effects of orlistat (a lipase enzyme inhibitor) or telmisartan (an angiotensin receptor blocker) on the serum free fatty acids in non-alcoholic fatty liver disease patients taking into consideration the baseline lipid profile.

Methods: This open-label clinical trial was carried out in the Department of Pharmacology, College of Medicine at the University of Sulaimani in cooperation with Shar Teaching Hospital in Sulaimani city-Kurdistan Region of Iraq. A total number of 74 non-alcoholic fatty liver disease patients were recruited and grouped randomly into group I (n = 25) treated with orlistat (120 mg/day orally) for 12 weeks, group II (n = 24) treated with telmisartan (20 mg/day orally) for 8 weeks, and group III (n = 25) treated with placebo (carboxy- methyl cellulose) once daily. Fasting serum level of free fatty acid and lipid profile including total cholesterol, triglyceride, high-density lipoprotein, and non-high-density lipoproteins were determined.

Results: Orlistat and telmisartan significantly reduced the triglyceride-glucose index and free fatty acid levels (P < .001) in patients with non-alcoholic fatty liver diseases.

Conclusion: Short-term treatment with orlistat or telmisartan produce effective and significant reductions in FFAs in patients with non-alcoholic fatty liver disease compared to placebo. Orlistat effectively reduces the free fatty acid irrespective of the baseline lipid profile.

Citing Articles

Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.

Subramaniyan V, Hanim Y Int J Obes (Lond). 2025; .

PMID: 40016558 DOI: 10.1038/s41366-025-01729-1.

Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy.

Zhang C, Liu S, Yang M World J Hepatol. 2023; 15(2):180-200.

PMID: 36926234 PMC: 10011909. DOI: 10.4254/wjh.v15.i2.180.

Pharmacological Support for the Treatment of Obesity-Present and Future.

Kosmalski M, Deska K, Bak B, Rozycka-Kosmalska M, Pietras T Healthcare (Basel). 2023; 11(3).

PMID: 36767008 PMC: 9914730. DOI: 10.3390/healthcare11030433.

References

Mannucci E, Dicembrini I, Rotella F, Rotella C . Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis. 2007; 18(5):342-8. DOI: 10.1016/j.numecd.2007.03.010. View

Dias S, Paredes S, Ribeiro L . Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018; 2018:2637418. PMC: 5822899. DOI: 10.1155/2018/2637418. View

Cui X, Chen S . White adipose tissue browning and obesity. J Biomed Res. 2017; 31(1):1-2. PMC: 5274505. DOI: 10.7555/JBR.31.20160101. View

Bochar O . Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. Wiad Lek. 2015; 67(2 Pt 2):157-60. View

Simental-Mendia L, Rodriguez-Moran M, Guerrero-Romero F . The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008; 6(4):299-304. DOI: 10.1089/met.2008.0034. View

Bessone F, Razori M, Roma M . Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2018; 76(1):99-128. PMC: 11105781. DOI: 10.1007/s00018-018-2947-0. View

Song J, Ruan X, Gu M, Wang L, Wang H, Mueck A . Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol. 2017; 34(5):413-417. DOI: 10.1080/09513590.2017.1407752. View

Choi G, Kim H, Kang H, Kim J . Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016; 32(7):1303-9. DOI: 10.1185/03007995.2016.1171204. View

Browning J, Horton J . Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114(2):147-52. PMC: 449757. DOI: 10.1172/JCI22422. View

10.

Bechmann L, Gieseler R, Sowa J, Kahraman A, Erhard J, Wedemeyer I . Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010; 30(6):850-9. DOI: 10.1111/j.1478-3231.2010.02248.x. View

11.

Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou Y . Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates. Int J Biol Sci. 2019; 15(2):265-276. PMC: 6367556. DOI: 10.7150/ijbs.30121. View

12.

Rong X, Li Y, Ebihara K, Zhao M, Naowaboot J, Kusakabe T . Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia. 2010; 53(8):1727-31. DOI: 10.1007/s00125-010-1744-6. View

13.

Fujii J, Homma T, Kobayashi S, Seo H . Mutual interaction between oxidative stress and endoplasmic reticulum stress in the pathogenesis of diseases specifically focusing on non-alcoholic fatty liver disease. World J Biol Chem. 2018; 9(1):1-15. PMC: 6198288. DOI: 10.4331/wjbc.v9.i1.1. View

14.

Hariri M, Zohdi S . Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials. Int J Prev Med. 2019; 10:14. PMC: 6360993. DOI: 10.4103/ijpvm.IJPVM_499_17. View

15.

Kujawska-Luczak M, Szulinska M, Skrypnik D, Musialik K, Swora-Cwynar E, Kregielska-Narozna M . The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. J Physiol Pharmacol. 2019; 69(5). DOI: 10.26402/jpp.2018.5.08. View

16.

Weiskirchen R, Tacke F . Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease. Cells. 2019; 8(1). PMC: 6357193. DOI: 10.3390/cells8010016. View

17.

Mantovani A . Time to revise the definition of NAFLD: A purist vision. Dig Liver Dis. 2019; 51(3):457-458. DOI: 10.1016/j.dld.2018.12.018. View

18.

Tan K, Tso A, Tam S, Pang R, Lam K . Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet Med. 2002; 19(11):944-8. DOI: 10.1046/j.1464-5491.2002.00823.x. View

19.

Hetherington A, Sawyez C, Zilberman E, Stoianov A, Robson D, Borradaile N . Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells. Cell Physiol Biochem. 2016; 39(4):1648-62. DOI: 10.1159/000447866. View

20.

Harms M, Seale P . Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013; 19(10):1252-63. DOI: 10.1038/nm.3361. View